Cyclin-Dependent Kinase 6
"Cyclin-Dependent Kinase 6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 6 associates with CYCLIN D and phosphorylates RETINOBLASTOMA PROTEIN during G1 PHASE of the CELL CYCLE. It helps regulate the transition to S PHASE and its kinase activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P18.
| Descriptor ID |
D051361
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.937 D12.644.360.250.515 D12.776.167.200.515 D12.776.476.250.515
|
| Concept/Terms |
Cyclin-Dependent Kinase 6- Cyclin-Dependent Kinase 6
- Cyclin Dependent Kinase 6
- Cell Division Protein Kinase 6
- Cdk6 Protein Kinase
- Protein Kinase, Cdk6
- CDK6 Protein
- PLSTIRE Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 6".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 6".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 6" by people in this website by year, and whether "Cyclin-Dependent Kinase 6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 6" by people in Profiles.
-
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
-
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncol. 2019 Oct; 15(29):3309-3326.
-
YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2019 04 01; 25(7):2264-2277.
-
Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. Sci Rep. 2018 02 09; 8(1):2709.
-
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A. 2010 Jun 22; 107(25):11501-6.